These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28507282)

  • 1. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
    Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
    Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
    Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
    Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
    Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
    Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
    Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
    Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
    BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
    Foskolou IP; Jorgensen C; Leszczynska KB; Olcina MM; Tarhonskaya H; Haisma B; D'Angiolella V; Myers WK; Domene C; Flashman E; Hammond EM
    Mol Cell; 2017 Apr; 66(2):206-220.e9. PubMed ID: 28416140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
    Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
    J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
    Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
    Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
    Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
    Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
    Rahman MA; Amin AR; Wang D; Koenig L; Nannapaneni S; Chen Z; Wang Z; Sica G; Deng X; Chen ZG; Shin DM
    Clin Cancer Res; 2013 Jul; 19(13):3416-28. PubMed ID: 23719266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
    Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
    Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.
    Taricani L; Shanahan F; Malinao MC; Beaumont M; Parry D
    PLoS One; 2014; 9(11):e111714. PubMed ID: 25375241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
    Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
    Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
    Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
    Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
    Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
    Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
    Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.